AbelZeta Pharma

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland, and Shanghai, China. AbelZeta focuses on developing innovative and proprietary cell-based therapeutic products and is committed to introducing customized therapies that harness the human body's own immune system to combat hematologic malignancies and solid tumors, as well as inflammatory and immune diseases. AbelZeta advances its R&D through its own GMP facility at its early clinical research center of excellence, with a pipeline that includes CAR-T and TIL therapies.On November 20, 2023, CBMG Holdings (Cellular Biomedicine Group) announced the spin-off of the company’s stem cell business unit and changed the company name to AbelZeta Pharma.